Quick Summary
Yohimbe (Pausinystalia johimbe) is a botanical traditionally used as a general tonic, aphrodisiac, and performance enhancer. Despite these traditional uses and its inclusion in various dietary supplements, current clinical evidence does not support clear efficacy for athletic performance enhancement or erectile dysfunction. Research also indicates potential herb-drug interactions and safety concerns associated with its use.
What is it
Yohimbe is a tree native to West Africa, and its bark extract contains alkaloids, primarily yohimbine, which have been used in traditional medicine. It is marketed in supplements aimed at improving sexual function and physical performance, though its clinical benefits remain unclear.
Traditional Uses
- General tonic
- Aphrodisiac
- Performance enhancer
These uses are based on ethnomedicine and traditional practices without validated clinical outcomes.
Active Compounds
The main active compounds in yohimbe bark extracts are indole alkaloids, with yohimbine being the most researched constituent. These alkaloids are thought to influence adrenergic receptors and various metabolic pathways.
Potential Benefits with Evidence Levels
- Erectile dysfunction: Insufficient clinical evidence. Systematic reviews highlight that herbs such as Panax ginseng and Tribulus terrestris show more promising results. Yohimbe and yohimbine lack strong evidence for improving erectile function.
- Athletic performance enhancement: Insufficient clinical evidence. A systematic review in elite soccer players found no supportive data that yohimbine supplementation improves jump height, sprint ability, or other performance metrics.
- Traditional tonic and aphrodisiac: Traditional use only. Yohimbe has a history of use as a general tonic and aphrodisiac based on ethnomedicine rather than robust clinical trials.
Side Effects
- Cardiac toxicity, including adverse cardiac events reported in post-marketing surveillance
- Hepatic toxicity
- Renal toxicity
- Other organ system toxicities documented in FDA’s CAERS database
Drug Interactions
Yohimbe extracts and their alkaloids can induce the pregnane X receptor (PXR) and cytochrome P450 enzymes, such as CYP3A4. They may also inhibit efflux transporters like P-glycoprotein. This suggests a potential for clinically relevant herb-drug interactions, especially with medications metabolized or transported through these pathways.
Who Should Avoid It
Although specific clinical contraindications are not well established, yohimbe should be used cautiously and under medical supervision. It may share contraindications similar to adrenergic and cardiovascular agents due to potential toxicities and interactions.
Use during pregnancy or breastfeeding is not recommended due to a lack of safety data and potential toxicity risks.
Evidence Limitations
- Lack of robust, high-quality randomized controlled trials evaluating yohimbe’s efficacy and safety for specific medical indications.
- Most safety data come from post-marketing adverse event reports and in vitro or preclinical studies, limiting causality assessments.
- Variability in botanical preparations and alkaloid content complicates comparability and reproducibility.
- Minimal regulatory oversight of dietary supplements containing yohimbe increases potential risks of adulteration and inconsistent dosing.
- Systematic reviews on herbal treatments for erectile dysfunction do not support efficacy of yohimbine or yohimbe-containing products.
References
- Annam SCVAR, et al. (2024). A Combined Approach for Rapid Dereplication of Herb-Drug Interaction Causative Agents in Botanical Extracts-A Molecular Networking Strategy To Identify Potential Pregnane X Receptor (PXR) Modulators in Yohimbe. Europe PMC. PMID: 39758619.
- Abreu R, Oliveira CB, et al. (2023). Effects of dietary supplements on athletic performance in elite soccer players: a systematic review. Europe PMC. PMID: 37462346.
- Leisegang K, Finelli R. (2021). Alternative medicine and herbal remedies in the treatment of erectile dysfunction: A systematic review. Europe PMC. PMID: 34552783.
- Li W, Wertheimer A. (2023). Narrative Review: The FDA’s Perfunctory Approach of Dietary Supplement Regulations Giving Rise to Copious Reports of Adverse Events. Europe PMC. PMID: 38035313.
- Husain I, et al. (2023). Screening of medicinal plants for possible herb-drug interactions through modulating nuclear receptors, drug-metabolizing enzymes and transporters. Europe PMC. PMID: 36223846.
- Krzykwa J, et al. (2025). Developing an approach for evaluating the cardiotoxic potential of botanicals. Europe PMC. PMID: 41244630.
Last Reviewed
June 2024
Disclaimer: This information is provided for educational purposes and is not intended as medical advice. Always consult with a qualified healthcare professional before using any herbal supplements, especially if you have underlying health conditions or are taking medications.